Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2001-11-02
2004-11-23
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S025000, C514S027000, C514S034000, C514S04400A, C514S049000, C514S117000, C514S403000, C514S404000, C514S449000, C514S471000, C514S472000, C514S479000, C514S492000, C514S588000, C514S592000, C514S593000, C514S595000, C514S596000, C514S597000, C514S598000, C514S602000, C514S603000, C514S604000, C514S605000
Reexamination Certificate
active
06822001
ABSTRACT:
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
Not applicable
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to combinations of pentafluorobenzenesulfonamides and various other chemotherapeutic agents that are capable of inhibiting abnormal cell proliferation.
2. Background
Cancer is a generic name for a wide range of cellular malignancies characterized by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize. These neoplastic malignancies affect, with various degrees of prevalence, every tissue and organ in the body. A multitude of therapeutic agents have been developed over the past few decades for the treatment of various types of cancer. The most commonly used types of anticancer agents include: DNA-alkylating agents (e.g., cyclophosphamide, ifosfamide), antimetabolites (e.g., methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist), microtubule disrupters (e.g., vincristine, vinblastine, paclitaxel), DNA intercalators (e.g., doxorubicin, daunomycin), and hormone therapy (e.g., tamoxifen, flutamide). The ideal antineoplastic drug would kill cancer cells selectively, with a wide therapeutic index relative to its toxicity towards non-malignant cells. It would also retain its efficacy against malignant cells, even after prolonged exposure to the drug. Unfortunately, none of the current chemotherapies possess an ideal profile. Most possess very narrow therapeutic indexes and, in practically every instance, cancerous cells exposed to slightly sublethal concentrations of a chemotherapeutic agent will develop resistance to such an agent, and quite often cross-resistance to several other antineoplastic agents.
The development of new anticancer agents has given rise to new treatment regimens and new combinations that are proving more effective in combating this disease.
Accordingly, it is one object of the present invention to provide compositions which directly or indirectly are toxic to actively dividing cells and are useful in the treatment of cancer.
A further object of the present invention is to provide methods for killing actively proliferating cells, such as cancerous, bacterial, or epithelial cells, and treating all types of cancers, and generally proliferative conditions. A further object is to provide methods for treating other medical conditions characterized by the presence of rapidly proliferating cells, such as psoriasis and other skin disorders.
Additional objects, features and advantages will become apparent to those skilled in the art from the following description and claims.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides compositions useful for the treatment of cancer and other diseases associated with abnormal cell proliferation. The compositions comprise an antineoplastic agent, including but not limited to prodrugs thereof, pharmaceutically acceptable salts of these agents and a compound having the formula:
In the formula above, the letter R represents a hydrogen, substituted or unsubstituted (C
1
-C
10
)alkyl, or substituted or unsubstituted (C
3
-C
6
)alkenyl. The symbol Ar represents a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
Suitable antineoplastic or antiproliferative agents include, but are not limited to, DNA-alkylating agents (e.g., cyclophosphamide, BCNU, busulfan and temozolamide), antimetabolites, antifolates and other inhibitors of DNA synthesis (e.g., methotrexate, 5-fluorouracil, gemcitabine), microtubule disruptors (e.g., vincristine, vinorelbine, paclitaxel, docetaxel), DNA intercalators (e.g., doxorubicin, daunomycin), hormone agents (e.g., tamoxifen, flutamide), topoisomerase I/II inhibitors and DNA repair agents (e.g., hydroxyurea, camptothecin, etoposide), growth factor receptor kinase inhibitors (e.g., AG1478 and AG1296), biological response modifiers (including cytokines such as interferon &agr; and growth factor inhibitors), antiangiogenic and antivascular agents (e.g., combretastatin A-4), and other agents such as immunoconjugates (e.g., trasuzamab) and antisense oligonucleotides.
The compositions will, in some embodiments, contain a pharmaceutically acceptable carrier or diluent.
In another aspect, the present invention provides methods for the treatment of cancer and other proliferative disorders using the compositions provided above, or using the components in a sequential or simultaneous administration.
REFERENCES:
patent: 1955207 (1934-04-01), Slotter et al.
patent: 2358365 (1944-09-01), Tullar
patent: 2402623 (1946-06-01), Hester et al.
patent: 2450863 (1948-10-01), Altamura et al.
patent: 2937202 (1960-05-01), Slagh et al.
patent: 3034955 (1962-05-01), Frick et al.
patent: 3322828 (1967-05-01), Muth et al.
patent: 3505455 (1970-04-01), Gipstein et al.
patent: 3951910 (1976-04-01), Mark
patent: 4013621 (1977-03-01), Knell
patent: 4034110 (1977-07-01), Mitrovic et al.
patent: 4080379 (1978-03-01), Seng et al.
patent: 4123553 (1978-10-01), Mitrovic et al.
patent: 4239699 (1980-12-01), MacKay et al.
patent: 4258058 (1981-03-01), Witte et al.
patent: 4373017 (1983-02-01), Masukawa et al.
patent: 4443477 (1984-04-01), Witte et al.
patent: 4483986 (1984-11-01), Dominianni
patent: 4692466 (1987-09-01), Yoshimoto et al.
patent: 4851445 (1989-07-01), Yoshimoto et al.
patent: 4870107 (1989-09-01), Yoshimoto et al.
patent: 4881969 (1989-11-01), Saupe et al.
patent: 4883914 (1989-11-01), Alvarado et al.
patent: 4900867 (1990-02-01), Wilkes et al.
patent: 4918106 (1990-04-01), Yoshimoto et al.
patent: 5143937 (1992-09-01), Lang et al.
patent: 5189211 (1993-02-01), Sato et al.
patent: 5250549 (1993-10-01), Yoshino et al.
patent: 5280043 (1994-01-01), Cooper et al.
patent: 5385931 (1995-01-01), Bigg et al.
patent: 5387709 (1995-02-01), Lardy et al.
patent: 5464826 (1995-11-01), Grindley et al.
patent: 5610320 (1997-03-01), Yoshino et al.
patent: 5773236 (1998-06-01), Diwu et al.
patent: 5780483 (1998-07-01), Widdowson et al.
patent: 5880151 (1999-03-01), Medina et al.
patent: 5891917 (1999-04-01), Tang et al.
patent: 6121304 (2000-09-01), Flygare et al.
patent: 6153585 (2000-11-01), Rubenstein et al.
patent: 6211167 (2001-04-01), Houze
patent: 6214880 (2001-04-01), Houze
patent: 6284923 (2001-09-01), Medina et al.
patent: 6316484 (2001-11-01), Flygare et al.
patent: 6355628 (2002-03-01), Schwender et al.
patent: 6465448 (2002-10-01), Gerson et al.
patent: 6482860 (2002-11-01), Flygare et al.
patent: 6528513 (2003-03-01), Cushing et al.
patent: 6583165 (2003-06-01), Houze
patent: 6630513 (2003-10-01), Rubenstein et al.
patent: 2002/0143036 (2002-10-01), Flygare et al.
patent: 2003/0162817 (2003-08-01), Flygare et al.
patent: 2003/0207864 (2003-11-01), Houze
patent: 622 494 (1935-11-01), None
patent: 3535167 (1987-04-01), None
patent: 36 23 184 (1988-01-01), None
patent: 3821540 (1989-12-01), None
patent: 0 391 799 (1990-10-01), None
patent: 0 469 901 (1992-02-01), None
patent: 0 472 449 (1992-02-01), None
patent: 0 472 053 (1999-02-01), None
patent: 2456731 (1980-12-01), None
patent: 859 345 (1961-01-01), None
patent: 938 890 (1963-10-01), None
patent: 1 189 720 (1970-04-01), None
patent: 1 242 057 (1971-08-01), None
patent: 1 306 564 (1973-02-01), None
patent: WO 97/30677 (1997-08-01), None
patent: WO 98/05315 (1998-02-01), None
patent: WO 98/05315 (1998-02-01), None
patent: WO 98/16227 (1998-04-01), None
patent: WO 98/22101 (1998-05-01), None
patent: WO 99/67258 (1999-12-01), None
patent: WO 00/17159 (2000-03-01), None
patent: WO 00/35865 (2000-06-01), None
patent: WO 00/61142 (2000-10-01), None
patent: WO 00/73264 (2000-12-01), None
patent: WO 01/08693 (2001-02-01), None
Fielding et al, “Synthesis and Reactions of 4-sulpho-2,3,5,6-Tetrafluorobenzoic Acid”;Journal of Fluorine Chemistry, vol. 59, No. 1, pp. 15-31 (1992).
Raibekas et al. “Affinity Probing of Flavia Binding Sites. 2. Identification of Reactive cysteine in the Flavin Domain ofEscherichia coliDNA Photolyase”;Biochemistry, vol. 33, No. 42, pp. 12656-12664
Schwendner Susan
Timmermans Pieter
Walling Jacqueline
Krass Frederick
Tularik Inc.
LandOfFree
Combination therapy using pentafluorobenzenesulfonamides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using pentafluorobenzenesulfonamides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using pentafluorobenzenesulfonamides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3355723